The company ditches lorigerlimab in prostate cancer.
ApexOnco Front Page
Recent articles
But the Day One deal is still 29% below where the shares stood at the start of this year.
A new batch of CRLs includes fresh revelations about patritumab deruxtecan.
Ocular toxicities could be the reason.
The group cans ZW171 after “on-target, off-tumour toxicity”.
As pivotal data approach, the French group pays $210m for ex-US rights.
Boehringer’s Hernexeos beats Bayer’s sevabertinib to the US.
Duality takes its Adam9-targeting conjugate into the clinic.
